Glucagon-like peptide-1 (GLP-1) receptor agonists have emerged as a pivotal class of medications primarily used in the treatment of type 2 diabetes mellitus (T2DM) and obesity [1, 2]. The gene discussed is GLP1R; the disease is diabetes mellitus.